Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Specialty Channel

Acute Myeloid Leukemia
Specialty Channel
Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
News
Patients With Acute Myeloid Leukemia and Concurrent DNMT3A and TET2 Mutations Demonstrate Lower Survival Outcomes
07/17/2025
Emily Estrada
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML,...
07/17/2025
Oncology
News
Venetoclax and CPX-531 Demonstrates Promising Activity Among Patients With Relapsed/Refractory Acute Myeloid Leukemia
07/10/2025
Emily Estrada
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax...
07/10/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Conference Coverage
Ziftomenib Achieves Durable Responses in R/R NPM1-Mutant AML Regardless of Prior Venetoclax Exposure: Pivotal KOMET-001 Results
06/12/2025
Emily Estrada
Ziftomenib monotherapy demonstrated deep and durable responses among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia, according to a phase 1b/2 trial.
Ziftomenib monotherapy demonstrated deep and durable responses among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia, according to a phase 1b/2 trial.
Ziftomenib monotherapy...
06/12/2025
Oncology
Conference Coverage
Real-World Data Confirms CPX-351 Efficacy and Safety for Newly Diagnosed t-AML and AML-MRC, With Enhanced Outcomes in Younger Patients and MR-Mutated Disease
06/05/2025
Emily Estrada
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Treatment with CPX-351 for...
06/05/2025
Oncology
Conference Coverage
Olutasidenib Shows Improved Efficacy in Earlier Lines of Therapy for R/R IDH1-Mutant AML
06/05/2025
Emily Estrada
Among patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence.
Among patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence.
Among patients with...
06/05/2025
Oncology
News
Tislelizumab Plus HMA and CAG Regimen Shows Improved Response Rates for Relapsed/Refractory AML
05/08/2025
Emily Estrada
Additional tislelizumab to standard hypomethylating agent plus CAG chemotherapy demonstrated improved cancer outcomes among patients with relapsed/refractory acute myeloid leukemia.
Additional tislelizumab to standard hypomethylating agent plus CAG chemotherapy demonstrated improved cancer outcomes among patients with relapsed/refractory acute myeloid leukemia.
Additional tislelizumab to...
05/08/2025
Oncology
News
Venetoclax Plus Hypomethylating Agent Treatment Shows Promise for Patients With Mutated AML
05/08/2025
Emily Estrada
For patients with an FLT3- or IDH1/2- mutated acute myeloid leukemia, venetoclax-HMA therapy demonstrates potential for the treatment of patients with AML, according to a systematic review and meta-analysis.
For patients with an FLT3- or IDH1/2- mutated acute myeloid leukemia, venetoclax-HMA therapy demonstrates potential for the treatment of patients with AML, according to a systematic review and meta-analysis.
For patients with an FLT3- or...
05/08/2025
Oncology

News

News
Patients With Acute Myeloid Leukemia and Concurrent DNMT3A and TET2 Mutations Demonstrate Lower Survival Outcomes
07/17/2025
Emily Estrada
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML,...
07/17/2025
Oncology
News
Venetoclax and CPX-531 Demonstrates Promising Activity Among Patients With Relapsed/Refractory Acute Myeloid Leukemia
07/10/2025
Emily Estrada
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax...
07/10/2025
Oncology
Conference Coverage
Ziftomenib Achieves Durable Responses in R/R NPM1-Mutant AML Regardless of Prior Venetoclax Exposure: Pivotal KOMET-001 Results
06/12/2025
Emily Estrada
Ziftomenib monotherapy demonstrated deep and durable responses among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia, according to a phase 1b/2 trial.
Ziftomenib monotherapy demonstrated deep and durable responses among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia, according to a phase 1b/2 trial.
Ziftomenib monotherapy...
06/12/2025
Oncology
Conference Coverage
Real-World Data Confirms CPX-351 Efficacy and Safety for Newly Diagnosed t-AML and AML-MRC, With Enhanced Outcomes in Younger Patients and MR-Mutated Disease
06/05/2025
Emily Estrada
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Treatment with CPX-351 for...
06/05/2025
Oncology
Conference Coverage
Olutasidenib Shows Improved Efficacy in Earlier Lines of Therapy for R/R IDH1-Mutant AML
06/05/2025
Emily Estrada
Among patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence.
Among patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence.
Among patients with...
06/05/2025
Oncology
News
Tislelizumab Plus HMA and CAG Regimen Shows Improved Response Rates for Relapsed/Refractory AML
05/08/2025
Emily Estrada
Additional tislelizumab to standard hypomethylating agent plus CAG chemotherapy demonstrated improved cancer outcomes among patients with relapsed/refractory acute myeloid leukemia.
Additional tislelizumab to standard hypomethylating agent plus CAG chemotherapy demonstrated improved cancer outcomes among patients with relapsed/refractory acute myeloid leukemia.
Additional tislelizumab to...
05/08/2025
Oncology
News
Venetoclax Plus Hypomethylating Agent Treatment Shows Promise for Patients With Mutated AML
05/08/2025
Emily Estrada
For patients with an FLT3- or IDH1/2- mutated acute myeloid leukemia, venetoclax-HMA therapy demonstrates potential for the treatment of patients with AML, according to a systematic review and meta-analysis.
For patients with an FLT3- or IDH1/2- mutated acute myeloid leukemia, venetoclax-HMA therapy demonstrates potential for the treatment of patients with AML, according to a systematic review and meta-analysis.
For patients with an FLT3- or...
05/08/2025
Oncology
News
Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML
04/09/2025
Emily Estrada
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world...
04/09/2025
Oncology
News
Chidamide and CAG Plus Venetoclax-Azacitidine Regimen Demonstrates High Response Rates in Older Patients With Acute Myeloid Leukemia
04/04/2025
Emily Estrada
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
An induction therapy regimen of...
04/04/2025
Oncology
News
ITGB7, SCD, and CD69 Expression Correlated With Overall Survival in Acute Myeloid Leukemia
04/03/2025
Emily Estrada
Researchers identified higher expression of CD69, ITBG7, SCD genes as prognostic indicators of disease and survival in a retrospective analysis.
Researchers identified higher expression of CD69, ITBG7, SCD genes as prognostic indicators of disease and survival in a retrospective analysis.
Researchers identified higher...
04/03/2025
Oncology

Interactive Features

Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology
Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology
Quiz
Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML
02/15/2024
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated...
02/15/2024
Oncology
Quiz
Humanized Bispecific Antibody Vibecotamab for R/R AML
02/07/2024
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering...
02/07/2024
Oncology
Quiz
Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy
01/10/2024
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to...
01/10/2024
Oncology
Quiz
Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML
12/09/2023
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did...
12/09/2023
Oncology

Recent Stories

Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
News
Patients With Acute Myeloid Leukemia and Concurrent DNMT3A and TET2 Mutations Demonstrate Lower Survival Outcomes
07/17/2025
Emily Estrada
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML,...
07/17/2025
Oncology
News
Venetoclax and CPX-531 Demonstrates Promising Activity Among Patients With Relapsed/Refractory Acute Myeloid Leukemia
07/10/2025
Emily Estrada
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax...
07/10/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use